Back to today’s briefing

Story perspectives

Verve Therapeutics Soars 26% After Gene Therapy Success

4/14/2025

31 3

Summary

Story summary

Verve Therapeutics Inc. celebrated a significant breakthrough with its gene-editing therapy, Verve-102, showing no safety concerns and a remarkable 53% average drop in LDL cholesterol for high-dose participants. This encouraging news propelled Verve's shares up 26% to $4.12, marking a strong recovery from earlier losses this year.

1 of 1

Story summary

Verve Therapeutics Inc. celebrated a significant breakthrough with its gene-editing therapy, Verve-102, showing no safety concerns and a remarkable 53% average drop in LDL cholesterol for high-dose participants. This encouraging news propelled Verve's shares up 26% to $4.12, marking a strong recovery from earlier losses this year.